# Alpha Genesis Supports Federal Research Applicants

Alpha Genesis is offering reduced-price preclinical study planning and research services to biotechnology firms, academic investigators, and research institutions preparing federal funding proposals. The offering is intended to help applicants scope studies and obtain project-specific estimates, timelines, and letters of interest; the article lists 2027 NIH and NSF submission dates. Separately, AGI Ventures accepts selected follow-on research or investment proposals on a rolling basis. These are vendor support and proposal-submission opportunities, not announced federal contract awards.

- Applicants can contact Alpha Genesis early to request estimates, timelines, or letters of interest for preclinical work supporting their proposals.
- The 2027 NIH and NSF dates may inform proposal planning, but specific dates are not provided in this signal.
- Biotechnology firms and research institutions may also submit eligible follow-on research or investment proposals to AGI Ventures for rolling consideration.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** November 12, 2026

### Government Entities
- National Institutes of Health (NIH)
- National Science Foundation (NSF)
- Advanced Research Projects Agency for Health (ARPA-H)
- U.S. Department of Defense (DoD)

### Vendors
- Alpha Genesis, Inc. (Preclinical contract research organization)
- AGI Ventures (Reviewer of selected follow-on research or investment proposals)

### Sources
- [Alpha Genesis | SBIR and Federal Preclinical Study Support](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/alpha-genesis-announces-full-service-preclinical-support-and-reduced-1250299) - ACCESS Newswire